id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-2099-0013,FDA,FDA-2020-D-2099,Sponsor Responsibilities —Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies; Guidance for Industry - Final Guidance,Other,Guidance,2025-12-16T05:00:00Z,2025,12,2025-12-16T05:00:00Z,,2025-12-24T10:00:21Z,,1,0,09000064b90dcab3
FDA-2020-D-2099-0012,FDA,FDA-2020-D-2099,"Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for Investigational New
Drug Application and Bioavailability/ Bioequivalence Studies; Guidance for Industry; Availability",Notice,Notice of Availability,2025-12-16T05:00:00Z,2025,12,2025-12-16T05:00:00Z,,2025-12-16T18:44:45Z,2025-22870,0,0,09000064b90da7e0
FDA-2020-D-2099-0002,FDA,FDA-2020-D-2099,Sponsor Responsibilities— Safety Reporting Requirements  and Safety Assessment for  IND and  Bioavailability/Bioequivalence Studies Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2021-06-28T04:00:00Z,2021,6,2021-06-28T04:00:00Z,,2021-06-28T13:17:39Z,,0,0,0900006484bb9a82
FDA-2020-D-2099-0001,FDA,FDA-2020-D-2099,"Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies; Draft 
Guidance for Industry; Availability",Notice,Notice of Availability,2021-06-28T04:00:00Z,2021,6,2021-06-28T04:00:00Z,2021-09-28T03:59:59Z,2021-09-28T01:00:46Z,2021-13684,0,0,0900006484bb9634